On November 23, 2019 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported that analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress ("ESMO Asia") on November 22 to 24, 2019 in Singapore (Press release, Hutchison China MediTech, NOV 23, 2019, https://www.chi-med.com/oral-presentations-at-2019-esmo-asia-annual-meeting/ [SID1234552849]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Savolitinib: the TATTON study was selected as a late-breaking presentation in the Presidential Session at ESMO (Free ESMO Whitepaper) Asia.
Presentation Title: TATTON Expansion Cohorts: A Phase Ib Study of Osimertinib Plus Savolitinib in Patients (pts) with EGFR-Mutant, MET-Positive NSCLC Following Disease Progression on a Prior EGFR-TKI
Presenting Author: Ji-Youn Han, Center for Lung Cancer, National Cancer Center, Korea
Other Authors: Lecia V. Sequist, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James C-H Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski, Sergey Orlov, Mireille Cantarini, Remy B. Verheijen, Anders Mellemgaard, Paul Frewer, Xiaoling Ou, Geoffrey Oxnard
Abstract #: LBA2
Session: Presidential Session
Date & Time: Saturday, November 23, 2019, 11:40 AM
Location: Suntec Singapore Convention & Exhibition Centre, Hall 406
Earlier results of this study (cut-off date of August 31, 2017) were first presented on October 17, 2017 at the World Conference on Lung Cancer (WCLC).[i] Interim results from this study (cut-off date of February 28, 2018) were presented on March 31, 2019 at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting[ii] (clinicaltrials.gov identifier: NCT02143466).
The TATTON trial supports SAVANNAH, an ongoing Phase II clinical trial exploring the combination of savolitinib and Tagrisso to overcome mesenchymal epithelial transition receptor ("MET")-driven endothelial growth factor receptor ("EGFR")-tyrosine kinase inhibitors ("TKI") resistance following treatment with Tagrisso (clinicaltrials.gov identifier: NCT03778229).
Savolitinib is a potent and selective inhibitor of MET, an enzyme which has been shown to function abnormally in many types of solid tumors. In clinical studies to date in over 1,000 patients globally, savolitinib has shown promising signs of clinical efficacy in patients with MET gene alterations in lung cancer, kidney cancer, and gastric cancer with an acceptable safety profile. Chi-Med is currently testing savolitinib in global partnership with AstraZeneca, both as a monotherapy and in combinations.
Fruquintinib (Elunate): Final results from the Phase II study of fruquintinib in combination with Iressa in China in the first-line setting for patients with advanced or metastatic non-small cell lung cancer ("NSCLC") with EGFR activating mutations will be presented. The primary objective of this exploratory study is to determine the safety and tolerability and median progression-free survival (PFS) of the fruquintinib and Iressa combination.
Presentation Title: Phase II Study of Fruquintinib Plus Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
Presenting Author: Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University
Other Authors: Jianying Zhou, Xiaomin Niu, Yiping Chen, Weiguo Su
Abstract #: 478O
Session: Mini Oral session – Thoracic cancers
Date & Time: Saturday, November 23, 2019, 5:00 PM
Location: Suntec Singapore Convention & Exhibition Centre, Hall 407
Earlier results of this study (cut-off date of October 10, 2017) were first presented on October 15, 2017 at the World Conference on Lung Cancer (WCLC)[iii] (clinicaltrials.gov identifier: NCT02976116).
Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor ("VEGFR") 1/2/3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage. Chi-Med retains all rights to fruquintinib outside of China and is partnered with Eli Lilly and Company in China.